Skip to content
value.today

Cellectis S.A. vs Moderna, Inc.

Add a company

Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.

In short

  • Moderna, Inc. is the larger company by market value: $90.1 B against $216 M for Cellectis S.A., 417 times as much (market caps of Jan 5, 2024 for Cellectis S.A. and Oct 30, 2026 for Moderna, Inc.). Cellectis S.A.'s value is the last on file, from Jan 5, 2024: no market-data feed is connected for its exchange yet.
  • Moderna, Inc. had more revenue: $1.9 B against $73 M for Cellectis S.A., both in the year to December 2025.
  • Both made a net loss: $68 M for Cellectis S.A. and $2.8 B for Moderna, Inc.
  • Cellectis S.A. keeps more of each dollar of sales: a net margin of -92.7% against -145.2% for Moderna, Inc.
  • Cellectis S.A.'s revenue grew faster in its latest fiscal year: +75.8% against -39.9% for Moderna, Inc.

Market value, the same start = 100

From Jan 2020: how each one's value moved, whatever its size.

0342685102713702020202120222023202420252026Cellectis S.A. 27Moderna, Inc. 1370

Revenue by fiscal year

US$ billions, as reported in each year's annual results.

$0B$5B$10B$14B$19B201720182019202020212022202320242025Cellectis S.A. $0BModerna, Inc. $2B

Side by side

Side-by-side comparison; ▲ marks the best value of a measure where higher or lower is better
MeasureCellectis S.A.
ALCLS.PA
Moderna, Inc.
MRNA · #275 in the world
Profile
Country🇫🇷 France🇺🇸 USA
SectorHealthcareHealthcare
IndustryBiotechnologyBiotechnology
Founded—2010
Size
Market cap$216 M*$90.1 B
Revenue$73 M$1.9 B
Net income$-68 M▲ best$-2.8 B
Employees—4,700
Valuation
Price to sales—35.7×
Price to book—10.4×
Free cash flow yield—-2.3%
Profitability
Gross margin—55.4%
Operating margin-45.4%▲ best-158.1%
Net margin-92.7%▲ best-145.2%
Return on equity-65.3%-28.9%▲ best
Growth
Revenue growth75.8%▲ best-39.9%
Revenue growth, 3 years a year—-53.4%
Financial strength
Debt to equity—0.1×
Interest cover-0.7×—
Cash
Free cash flow margin-57.2%▲ best-106.2%
Shareholder returns
Shareholder yield—0.0%
Strength scores
Piotroski F-score—3 of 9
Altman Z-score zone—safe
Data as ofMarket cap Jan 2024; ratios FY2025Market cap Oct 2026; ratios FY2025

▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither

Questions and answers#

Which is bigger, Cellectis S.A. or Moderna, Inc.?

Moderna, Inc. is the larger company by market value: $90.1 B against $216 M for Cellectis S.A., 417 times as much (market caps of Jan 5, 2024 for Cellectis S.A. and Oct 30, 2026 for Moderna, Inc.). Cellectis S.A.'s value is the last on file, from Jan 5, 2024: no market-data feed is connected for its exchange yet.

Which makes more money, Cellectis S.A. or Moderna, Inc.?

Moderna, Inc. had more revenue: $1.9 B against $73 M for Cellectis S.A., both in the year to December 2025. Both made a net loss: $68 M for Cellectis S.A. and $2.8 B for Moderna, Inc.

Which is more profitable, Cellectis S.A. or Moderna, Inc.?

Cellectis S.A. keeps more of each dollar of sales: a net margin of -92.7% against -145.2% for Moderna, Inc.

Which is growing faster, Cellectis S.A. or Moderna, Inc.?

Cellectis S.A.'s revenue grew faster in its latest fiscal year: +75.8% against -39.9% for Moderna, Inc.

Sources#

Every figure on this page comes from these, with the date shown next to it.